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S U M M A R Y
Background: Kaposi’s sarcoma (KS) is the most common neoplasm among HIV-infected individuals. The
frequency of involvement of KS in the gastrointestinal (GI) tract and the associated epidemiological,
immune, endoscopic, and histopathological features in HIV-infected patients, were evaluated in this
study.
Methods: A review of the medical and endoscopy reports of 1428 HIV-infected patients, who had
undergone upper GI endoscopy at the Endoscopy Service, Clinical Hospital, Faculty of Medicine of
Ribeira˜o Preto between January 1999 and June 2009, was performed. Clinical, epidemiological,
immunological, endoscopic, and histological data were collected.
Results: Twenty-seven (1.9%) patients were diagnosed with GI KS. Patients were predominantly male
(81.5%). Sexual activity was the main route of HIV transmission (81.5%). Cutaneous involvement was
noted in 21 patients (78%). Fifteen patients (55%) received highly active antiretroviral therapy for a mean
duration of 12.6 weeks (range 2–52 weeks) before endoscopy. GI lesions were mainly found in the
stomach (55%). Analysis of the immunohistochemical methods HHV8 LNA-1, CD31, and CD34 for the
diagnosis of gastric KS indicated high agreement (kappa = 0.63, 95% conﬁdence interval 0.32–0.94).
There was no relationship between CD4 levels (p = 0.34) or HIV viral load (p = 0.99) and HHV8 LNA-1
positivity in gastric KS.
Conclusions: GI KS is an infrequent ﬁnding in patients with HIV infection. Among those with GI KS, 80%
had concomitant skin lesions. Immunohistochemical methods for CD31, CD34, and LNA-1 were
important tools in the diagnostic assessment of lesions suggestive of KS in the GI tract. Further studies
are required to conﬁrm these data, and the need for routine endoscopic investigation of the GI tract in
HIV-infected patients with cutaneous KS should be assessed.
 2015 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Kaposi’s sarcoma (KS) is a vascular tumor associated with
human herpesvirus 8 (HHV8) infection and is the most common
neoplasm among HIV-infected patients, affecting 15–20% of this
population.1,2 KS usually manifests as nodular lesions on the skin.
Visceral lesions are present in nearly 25% of patients with HIV-
associated KS.3* Corresponding author.
E-mail address: rosamarrezende@uol.com.br (R.E.F. Rezende).
http://dx.doi.org/10.1016/j.ijid.2015.09.006
1201-9712/ 2015 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/4.0/).Gastrointestinal (GI) KS lesions can be present in HIV-positive
patients independent of cutaneous disease.4 GI lesions may be
asymptomatic or cause mild symptoms such as nausea and
vomiting.3,4 In some cases, it may lead to hemorrhage, abdominal
pain, gastric outlet obstruction, or intussusception.3,5–7
KS can be diagnosed at any stage of HIV infection, although it is
more commonly related to severe immune suppression, especial-
ly with an elevated HIV viral load.8 Endoscopically, GI KS can
vary from erythematous lesions to maculopapular or polypoid
lesions.9 However, the histopathological diagnosis of the tumor
may be difﬁcult because of the submucous localization of the
lesion. Immunohistochemistry techniques, including the use ofious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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to detect HHV8 in tissues, have been considered useful tools for
the diagnosis of KS.10,11
The objective of this study was to evaluate the prevalence and
the clinical and pathological presentations of GI KS among HIV-
infected patients undergoing upper endoscopy.
2. Methods
2.1. Study design and data collection
An observational, retrospective and descriptive study was
conducted of 1428 HIV-infected Brazilian patients who underwent
upper GI endoscopy at the Endoscopy Service of the Specialized
Unit for the Treatment of Infectious Diseases, Clinical Hospital,
Faculty of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo
(HCFMRP-USP) between January 1999 and June 2009. The upper GI
endoscopy was requested for investigation of symptoms related or
not to dyspepsia and also for staging of KS.
Inclusion criteria included patients of both sexes, age >18 years,
and the presence of lesions suggestive of KS detected by upper GI
endoscopy. Twenty-seven (1.9%) HIV-infected patients with KS
detected by upper GI endoscopy met the inclusion criteria.
The following data were obtained: age, sex, risk factors for HIV
infection, symptoms related to gastrointestinal KS, time elapsed
from the HIV diagnosis to ﬁrst endoscopy, assessment of extra-
intestinal manifestations, and use of highly active antiretroviral
therapy (HAART).
2.2. Ethics statement
The study was conducted in accordance with the Declaration of
Helsinki (1975) and was approved by the Ethics Committee of the
Clinical Hospital and Faculty of Medicine of Ribeira˜o Preto,
University of Sa˜o Paulo (under process 10341/2009; e-mail
cep@hcrp.fmrp.usp.br). The Ethics Committee of the Clinical
Hospital and Faculty of Medicine of Ribeira˜o Preto, University of
Sa˜o Paulo, waived the need for consent for upper GI endoscopy and
for the use of histopathological samples. The authors used
anonymized data from patient medical records. The present data
have not been used in previous publications. There are no ethical
issues related to the present study and the publication of this
manuscript.
2.3. Serum determination of CD4+ T lymphocytes
The CD4 count was measured by ﬂow cytometry, preferably
within 6 months prior to or up to 6 months following endoscopy
for patients who had not been subjected to a previous CD4 count.
2.4. HIV viral load testing
Viral plasma load was determined by branched DNA assay
(Versant HIV-1 RNA 3.0; Siemens Healthcare Diagnostics Inc.,
Tarrytown, NY, USA) within 6 months prior to or up to 6 months
following endoscopy for patients with no previous determination
of viral load.
2.5. Endoscopic procedure
Upper GI endoscopy was performed using a Pentax EG
2901 endoscope (9.8 mm; Pentax, Tokyo, Japan). During the upper
GI endoscopy, photographs and biopsies of the KS lesions were
obtained. All endoscopic procedures were performed or reviewed
by the same experienced endoscopist (R.E.F.R.).KS lesions were evaluated on endoscopy and macroscopic
ﬁndings were characterized using the classiﬁcation proposed by
Ahmed et al.12 Three different endoscopic appearances of KS
lesions were noted: type 1 or maculopapular lesions, character-
ized by a slight elevation of the mucosal surface, dark pink/scarlet
in color, with a diameter of 2–5 mm; type 2 or polypoid lesions,
characterized by nodular or papular lesions, darker in color, with a
regular or irregular surface 1 cm in diameter; type 3 or volcano-
like lesions, characterized by nodular lesions with a central
depression, generally greater in size (>1 cm diameter).12 KS
lesions were also evaluated in terms of the site of upper GI
involvement: esophagus, stomach, or duodenum. A biopsy was
performed using multibite biopsy forceps (Multibite Microvasive
Endoscopy; Boston Scientiﬁc Corp, Natick, MA, USA). The number
of biopsy specimens obtained from each individual ranged from
3 to 20.
2.6. Histopathological and immunohistochemical study
A retrospective series of parafﬁn blocks and histopathology
slides of all lesions suggestive of KS identiﬁed during endoscopy
between 1999 and 2009 were reviewed and selected from the
archive of the Service of Pathology at HCFMRP-USP (SERPAT; URL
http://www.rpm.fmrp.usp.br/). Hematoxylin and eosin (HE) stain-
ing, investigation of HHV8 LNA-1, and immunohistochemistry for
CD31 and CD34 were performed for all cases. The histological
review was conducted by the same experienced pathologist
(M.O.B.).
For the immunohistochemical study, silanisated slides treated
with 4% organosilane solution diluted in acetone (3-aminopro-
pyltriethoxysilane; Sigma, St Louis, MO, USA) were prepared from
parafﬁn-embedded sections of 4 mm in thickness. The slides were
incubated with the following primary antibodies: mouse
monoclonal antibody anti-CD31 (NCL-1A10, 1:400), mouse
monoclonal antibody anti-CD34 (NCL-end, QBEnd/10, 1:100)
(Novocastra Laboratories, UK), and mouse monoclonal antibody
to HHV8 LNA-1 (clone 13B10, 1:100; Cell Marque Corporation,
USA).
Histological sections of human skin (known to be HHV8-
positive) and human tonsils were used as positive and negative
controls for CD34 and CD31. Control specimens were similarly
treated, except for no addition of primary antibody for the negative
control.
2.7. Statistical analysis
Descriptive statistics were used to summarize the demographic
data. The relationships between HIV viral load and CD4 serum
levels and the number of upper GI sites affected by KS, and the
relationships between CD4 serum levels, HIV viral load, and
number of KS lesions conﬁrmed by biopsy and HHV8-associated
gastric sarcoma were evaluated using Fisher’s exact test. The
statistical analyses were performed using SAS version 9.0 software.
Values of p < 0.05 were considered signiﬁcant.
The agreement between histological methods for the diagnosis
of gastric KS (LNA-1, CD31, CD34, and HE) was calculated using
Cohen’s kappa coefﬁcient. A kappa >0.61 was considered ‘good’
agreement, a kappa of 0.41–0.60 was considered ‘moderate’
agreement, and a kappa <0.40 was considered ‘low’ agreement.
3. Results
3.1. Demographic and epidemiological characteristics
A total of 1428 endoscopy reports were reviewed and
27 patients (1.9%) were diagnosed with KS. Patients with GI KS
Table 1
Clinical and epidemiological characteristics of 27 cases of Kaposi’s sarcoma in the
upper gastrointestinal tract
Total N = 27
Age, years, mean  SD (range) 39.8  10.2 (19–58)
Sex, male/female 22/5
Risk factor for HIV acquisition
Sexual preference 22 (81.5%)
Heterosexual 13 (48.1%)
Homosexual 6 (22.2%)
Bisexual 3 (11.1%)
Drugs 6 (22.2%)
Other 6 (22.2%)
Absence of gastrointestinal symptoms 22 (81.5%)
Interval between HIV diagnosis and
detection of gastrointestinal KS, years
<1 14 (51.8%)
1–5 6 (22.2%)
5–10 4 (14.9%)
>10 3 (11.1%)
Extra-intestinal KS
Pulmonary KS 15 (55.5%)
Skin KS 21 (77.7%)
Oral KS 6 (22.2%)
HAART before endoscopy 15 (55.5%)
Duration of HAART before endoscopy,
weeks, mean  SD (range)
12.6  14.9 (2–52)
CD4 lymphocyte count, cells/mm3 mean (range) 136 (2–676)
HIV-1 viral load, copies/ml, median (range) 117 000 (50–1 400 000)
SD, standard deviation; KS, Kaposi’s sarcoma; HAART, highly active antiretroviral
therapy.
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The major risk factor for HIV acquisition was sexual activity
(81.5%). Twenty-two patients (81.5%) with GI KS had no speciﬁc GI
symptoms. Cutaneous involvement was noted in 21 (78%) patients.
Fifteen patients (55%) received HAART for a mean duration of
12.6 weeks (range 2–52 weeks) before endoscopy.Figure 1. Endoscopic aspects of Kaposi lesions. (A) Esophagus macular lesions; (B) gastric
duodenum polypoid lesions.
Table 2
Distribution and macroscopic appearance of Kaposi’s sarcoma in the gastrointestinal tr
Frequency (%) Esophagus Esophagus +
stomach
Esophagus + stomach
duodenum
KS localization - 3.7 25.9 
Type 1
(Maculopapular lesion)
33.3 - - 
Type 2
(Polypoid lesion)
33.3 - - 
Type 3
(Volcano-like lesion)
- - - 
Types 1 and 2 22.2 - - 
Types 2 and 3 11.1 - - 
KS, Kaposi’s sarcoma.Clinical and epidemiological features of the study group are
given in Table 1.
3.2. Viral and immunological status
The patients with gastrointestinal KS had a median HIV-1 viral
load of 117 000 copies/ml (range 50–1 400 000 copies/ml) and a
mean CD4 lymphocyte count of 136 cells/mm3 (range 2–676 cells/
ml) (Table 1).
3.3. Upper gastrointestinal endoscopy ﬁndings
Gastrointestinal lesions were found in the stomach (55%),
esophagus, stomach and duodenum (26%), and stomach and
duodenum (7%) (Table 2).
Type 2 (polypoid) and type 1 (maculopapular) lesions were
most frequently noted in the stomach (48%) and duodenum (64%),
respectively (Figure 1). Concurrence of type 1 and type 2 lesions
was most frequently noted in the esophagus (22%) (Figure 1). Type
3 (volcano-like) lesions were noted exclusively in the stomach (8%)
(Table 2).
3.4. Histopathological ﬁndings
Agreement between histological methods for the diagnosis of
gastric KS (LNA-1, CD31, CD34, and HE) was calculated for 23
(85%) patients using Cohen’s kappa coefﬁcient. Immunohis-
tochemistry for LNA-1 was considered the gold standard
(Figure 2).
A low level of agreement was found between HE and LNA-1
(kappa = 0.21, 95% conﬁdence interval (CI) 0.02 to 0.43),
whereas high agreement was observed between LNA-1 and
CD31 methods (kappa = 0.63, 95% CI 0.32 to 0.94) and between
LNA-1 and CD34 methods (kappa = 0.63, 95% CI 0.32 to 0.94)
(Figure 2). maculopapular and polypoid lesions; (C) U-turn – giant gastric polypoid lesions; (D)
act on endoscopy, according to the upper gastrointestinal site
 + Esophagus + duodenum Stomach Stomach +
duodenum
Duodenum
3.7 55.5 7.4 3.7
- 24 - 63.6
- 48 - 36.4
- 8 - -
- 20 - -
- - - -
Figure 2. Different gastric histopathological study techniques. (A) Proliferation of fusiform cells at the level of the lamina propria arranged in short fascicles (HE 100, arrow).
Cells with positive immunohistochemical staining are stained brown: CD34 (B), CD31 (C), and HHV8 LNA-1 (D).
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by KS
In regard to CD4 levels and the number of sites affected by KS in
the upper GI tract, in the group of patients with CD4 <100 cells/
mm3 (n = 12), nine had KS at one upper GI site and two had KS at
two or more sites. In the group of patients with CD4 between
100 and 350 cells/mm3 (n = 10), ﬁve had KS at one site and ﬁve had
KS at two or more sites. In the group of patients with CD4 >350
cells/mm3 (n = 4), two had KS at one site and two had KS at two or
more sites. No signiﬁcant differences in CD4 count or number of
upper GI sites affected by KS were observed between groups
(p = 0.47).
Analysis of the HIV viral load and the number of upper GI
sites affected by KS showed that patients with a viral load <50
copies/ml (n = 2) presented KS at one upper GI site. Of the
patients with a viral load between 50 and 10 000 copies/ml
(n = 7), ﬁve presented KS at one upper GI site and two presented
KS at two or more sites, and among patients with a viral load
between 10 000 and 100 000 copies/ml (n = 6), three presented
KS at one upper GI site and three presented KS at two or more
sites. No signiﬁcant differences in HIV viral load or number of
upper GI sites affected by KS were observed between groups
(p = 0.62).3.6. Serum CD4, HIV viral load, and HHV8 LNA-1 positivity in gastric KS
In the group of patients with CD4 <100 cells/mm3, LNA-1 was
positive in the gastric tissue in 5/11 patients (45%). In the group of
patients with CD4 between 100 and 350 cells/mm3 (n = 10), LNA-1
was positive in 6/9 patients (67%). In the group of patients with
CD4 >350 cells/mm3, LNA-1 was positive in 2/2 patients (100%).
There was no signiﬁcant relationship between CD4 count and LNA-
1 positivity (p = 0.39).
In order to evaluate the relationship between HIV viral load and
LNA-1 in the stomach, patients were divided into four groups: in
group 1 (HIV viral load <50 copies/ml; n = 1), LNA-1 was positive;
in group 2 (HIV viral load between 50 and 10 000 copies/ml; n = 6),
LNA-1 was positive in four cases; in group 3 (HIV viral load
between 10 000 and 100 000 copies/ml; n = 5), LNA-1 was positive
in three cases; and in group 4 (HIV viral load >100 000 copies/ml;
n = 9), LNA-1 was positive in ﬁve cases. There was no signiﬁcant
relationship between HIV viral load and LNA-1 positivity (p = 0.99).
3.7. Number of biopsy specimens required for KS diagnosis by LNA-1
immunohistochemistry
The relationship between the number of biopsy specimens
collected from patients during endoscopy and the investigation of
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patients (42%) from whom less than ﬁve fragments of gastric tissue
were collected, and in 8/11 patients (73%) from whom more than
six fragments of gastric tissue were collected (p = 0.21).
4. Discussion
KS of the upper GI tract can be found in about 24% of individuals
with AIDS.13 The GI tract is the most frequent extracutaneous site
of AIDS-KS.
In general, GI KS is asymptomatic, but depending on the stage,
many clinical presentations may occur, including nausea, vomit-
ing, abdominal pain, and severe complications such as bleeding,
mechanical obstruction, and bowel perforation. In a case series, GI
organs frequently involved were the small intestine (30%), colon
(17%), and stomach (15%).14
The association between KS and infection with HHV8 has been
documented since 1994, when the viral DNA sequence of
herpesvirus was identiﬁed by Chang et al.2 A higher incidence
of HHV8 infection has been reported in homosexual men,
particularly among those with male sexual partners. Speciﬁc
practices including anal–genital and oral–genital contact have
been associated with higher HHV8 transmission and seroconver-
sion rates.
Similar to previous reports, the majority of patients in this study
were male.15,16 The great majority of the study group (81.5%) had
no GI symptoms, and the skin was the most common extra-
intestinal site affected by KS, followed by the lungs and oral cavity,
similar to results described previously.17,18 Pulmonary lesions are
generally asymptomatic and associated with concurrent cutane-
ous manifestations of KS.19
The role of HAART in the reduction of the incidence of
opportunistic infections and malignant neoplasms among HIV-
positive individuals is well established.1,20 In the present study,
55% of the patients were on HAART for a mean 3 months before
upper GI endoscopy. Similarly, Nagata et al. reported that 45% of
HIV-infected patients diagnosed with KS had undergone HAART for
a period of less than 12 months.17 The duration of HAART may be
correlated with KS lesions of less than 1 cm in size (type 1 or 2), as
found in the majority of the present study group. These endoscopic
ﬁndings may be associated with early regression KS induced by
treatment, or related to initial stage disease manifestation. Further
studies with a larger number of patients are necessary to evaluate
this association.
Endoscopic ﬁndings in the present study revealed the frequency
of KS lesions by site of upper GI involvement. In descending order,
KS lesions were noted mainly in the stomach (55%), followed by the
esophagus, stomach and duodenum concomitantly (26%), and
stomach and duodenum concomitantly (7%). As noted previous-
ly,8,17 a high viral load and low CD4 count are risk factors and
predispose patients to the manifestations of the disease, and
consequently the spread to multiple sites. The present study
population had a mean CD4 count of 136 cells/mm3 (Table 1) and a
median viral load of 117 000 copies/ml. Furthermore, this has
already been observed in previous studies, particularly involving
individuals with CD4 counts <200 cells/mm3.3,21,22 Thus, this
ﬁnding should alert endoscopists to actively investigate for KS in
the GI tract in this particular group of patients.
The risk of acquiring KS is directly related to impaired cell
immunity and a low CD4 count, which in turn increases the risk of
HIV seroconversion, possibly due to decreased interferon gamma.23
In the present study, analysis of the relationship between CD4 levels
and the number of upper GI sites involved by the disease showed an
incidence of 46% of KS lesions at one or more sites, with 25% at two or
more sites among patients with a CD4 count <100 cells/mm3. In
contrast, only 15% of patients with a CD4 >350 cells/mm3 presentedKS lesions at one or more gastrointestinal sites, with half of them at
two or more sites. Although this suggests the appearance of more
lesions in patients with CD4 <100 cells/mm3, this study was limited
by the relatively small number of patients and no statistical
signiﬁcance was identiﬁed for this association.
HIV viral load may also be considered a risk factor for KS in
patients with AIDS.8 KS lesions were noted at one or more upper GI
sites particularly in patients with an HIV viral load
>100 000 copies/ml (40%), and at a limited number of upper GI
sites among patients with an undetectable viral load (<50 copies/
ml) (8%). Once more, the small sample size may have contributed
to the lack of statistical difference between the groups.
Larger and more numerous lesions may be related to the
severity of endoscopic ﬁndings and may represent a risk factor for a
negative clinical outcome of the disease; this is generally
associated with the viral load and CD4 count.17 In the present
study, a predominance of lesions <1 cm in diameter was noted.
This indicates two possible hypotheses: an initial stage of the
disease in the upper GI tract of severely HIV-infected patients, or an
early improvement in the lesions during the ﬁrst months of HAART,
as described previously in the present cohort. However, more
studies are necessary before conclusions can be drawn. A
limitation of this study is the lack of an identiﬁed association
between the clinical outcome and the presence of lesions <1 cm in
diameter. Further studies on this association are to be encouraged,
which will probably reveal the rate of complications underlying
early KS.
Previous studies have reported that endoscopic biopsy has a
low diagnostic yield for KS lesions.24 In a recent study, the authors
investigated causes of false-negative results from endoscopic
biopsies of gastrointestinal KS lesions.25 The esophagus was the
main upper GI site signiﬁcantly associated with false-negative
results. Small size (<1 cm) and submucosal localization were also
associated with false-negative results. Moreover, it has been
suggested that the size of the biopsy forceps may affect the amount
or size of sample collected and the diagnostic yield for KS.26 The
number of specimens of gastric lesions collected using endoscopic
biopsy was evaluated in the present study and an immunohisto-
chemical method was used for the detection of LNA-1. A slight
increase in positive results for the test containing more than six
specimens was observed, but with no statistical signiﬁcance. Other
factors such as the type, size, and location of lesions seem to be
more relevant for KS diagnosis than the amount of sample obtained
from endoscopic biopsy.
Although the exact mechanism of KS pathogenesis has not been
clearly elucidated, a number of reports have suggested that chronic
endothelial cell proliferation, mediated by cytokines and possibly
associated with latent HHV8, causes changes in neoplastic cells.27
HHV8 is found in the lytic or predominantly in the latent phase in
the host, in KS fusiform tumor cells, lymphocytes, monocytes, and
keratinocytes.28 It remains unknown whether KS is derived from
vascular or lymphatic endothelium. While some studies have
demonstrated the existence of vascular endothelial markers in KS,
including CD31 and CD34,29 others have shown the expression by
KS of the speciﬁc lymphatic markers VEGFR-3, LYVE-1, and D2-40,
supporting a lymphatic origin for KS,30,31 or an origin from a
pluripotent cell type capable of undergoing both vascular and
lymphatic differentiation.27,32
HHV8 activity can be examined by tests able to detect the virus
or the host immune response to the infection. Immunohistochem-
istry for latency-associated nuclear antigen with anti-HHV8
antibody has been useful for detecting HHV8 in infected tissues
and this is considered a sensitive and speciﬁc marker of latent
infection with HHV8.10,11 In the present study, high agreement
between CD31/CD34 and LNA-1 was found, suggesting a vascular
origin of the disease. The expression of these markers is directly
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CD31 and negative for LNA-1 expression may represent recruited
endothelial cells that have not already been infected by HHV8.32 In
fact, this should alert physicians to the necessity of more frequent
testing for these speciﬁc markers when suspected KS lesions are
encountered on endoscopy.
The onset of KS is associated with high viral loads and low CD4
counts,8 and in vitro and in vivo studies have demonstrated that
LNA-1 may be detected at any stage of host cell infection.33 In the
data from the present study, no evidence of a relationship between
CD4 levels and LNA-1 positivity on immunohistochemistry was
found. Hence, LNA-1 immunoreactivity may not be correlated with
the patient’s immunological proﬁle, age, tumor recurrence, or site
of the lesions.34
In conclusion, GI KS is an infrequent ﬁnding in patients with HIV
infection. Among those with GI KS, 80% had concomitant skin
lesions. GI KS lesions were found mainly in the stomach (55%).
Immunohistochemical methods for CD31, CD34, and LNA-1 were
important tools in the diagnostic assessment of lesions suggestive
of KS in the GI tract. Further studies are required to conﬁrm these
data, and the need for routine endoscopic investigation of the GI
tract in HIV-infected patients with cutaneous KS should be
assessed.
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